BioLeap is a molecule design company that leverages its proprietary technology platform to identify and optimize lead compounds where other approaches have not been successful.


BioLeap creates novel compounds with intellectual property protection, enhances the intellectual property estate around existing compounds, avoids obstructive patents, and generates fast-follower compounds for early market entry. Learn more about how our technology can help solve your molecule discovery problems.


The BioLeap Advantage

The BioLeap Advantage

BioLeap has engineered a revolutionary, performance-optimized fragment-based algorithm which results in a practical method for reliably determining how fragments bind. Learn More


December 26, 2014

Ligand Engineering of PCSK9 Inhibitors | Read More

October 18, 2013

BioLeap Secures NIH Grant to Develop Small Molecule Inhibitor of PCSK9 | Read More

September 5, 2012

Fragment-Based Drug Design: Delivering Drugs That Hit Multiple targets, Leveraging Insights From Systems Biology | Read More